Monivent (MONI) Q4 2024 earnings summary

Executive summary

• 2024 marked a breakthrough year with strategic progress and a global distribution agreement with Drägerwerk AG & Co KGaA, positioning Monivent for international expansion.

• Regulatory milestones included a successful US user study and ongoing MDR and FDA processes for Neo100.

• A convertible loan of 3.9 MSEK was secured, followed by a 13 MSEK rights issue, strengthening liquidity for future commitments.

Financial highlights

• Net sales for 2024 were 2,142 KSEK, down from 3,572 KSEK year-over-year; Q4 net sales were 691 KSEK, down from 1,040 KSEK.

• Operating expenses for 2024 totaled 14,165 KSEK, down from 17,626 KSEK; Q4 expenses were 4,464 KSEK.

• EBIT for 2024 was -11,203 KSEK, an improvement from -13,903 KSEK in 2023; Q4 EBIT was -2,965 KSEK.

• Cash and cash equivalents at year-end were 970 KSEK, with an equity ratio of 11%.

• Earnings per share for 2024 were -0.54 SEK, compared to -1.35 SEK in 2023.

Outlook and guidance

• The Dräger agreement is expected to drive significant revenue growth in coming years, with a target to achieve positive cash flow by Q4 2027.

• Updated financial targets and business strategy were announced post-year-end.